Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.
Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, Plummer SA, Mascola JR, Bailer RT, Roederer M, Koup RA, Nabel GJ; VRC 008 Study Team. Graham BS, et al. Among authors: enama me. PLoS One. 2013;8(4):e59340. doi: 10.1371/journal.pone.0059340. Epub 2013 Apr 8. PLoS One. 2013. PMID: 23577062 Free PMC article. Clinical Trial.
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.
Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS. Martin JE, et al. Among authors: enama me. Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. doi: 10.1128/CVI.00162-06. Epub 2006 Sep 20. Clin Vaccine Immunol. 2006. PMID: 16988008 Free PMC article. Clinical Trial.
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS; Vaccine Research Center 006 Study Team. Catanzaro AT, et al. Among authors: enama me. J Infect Dis. 2006 Dec 15;194(12):1638-49. doi: 10.1086/509258. Epub 2006 Nov 8. J Infect Dis. 2006. PMID: 17109335 Free PMC article. Clinical Trial.
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ; Vaccine Research Center 004 Study Team. Graham BS, et al. Among authors: enama me. J Infect Dis. 2006 Dec 15;194(12):1650-60. doi: 10.1086/509259. Epub 2006 Nov 8. J Infect Dis. 2006. PMID: 17109336 Free PMC article. Clinical Trial.
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS; VRC 201/203 Study Team. Parrino J, et al. Among authors: enama me. Vaccine. 2007 Feb 9;25(8):1513-25. doi: 10.1016/j.vaccine.2006.10.047. Epub 2006 Nov 7. Vaccine. 2007. PMID: 17126963 Free PMC article. Clinical Trial.
Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.
Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, Gomez PL, Andrews CA, Koup RA, Bailer RT, Stein JA, Roederer M, Nabel GJ, Graham BS. Tavel JA, et al. Among authors: enama me. J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):601-5. doi: 10.1097/QAI.0b013e3180417cb6. J Acquir Immune Defic Syndr. 2007. PMID: 17325604 Free PMC article. Clinical Trial.
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS; VRC 007 Study Team. Catanzaro AT, et al. Among authors: enama me. Vaccine. 2007 May 16;25(20):4085-92. doi: 10.1016/j.vaccine.2007.02.050. Epub 2007 Mar 7. Vaccine. 2007. PMID: 17391815 Clinical Trial.
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.
Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS. Martin JE, et al. Among authors: enama me. J Infect Dis. 2007 Dec 15;196(12):1732-40. doi: 10.1086/523650. J Infect Dis. 2007. PMID: 18190252 Free PMC article. Clinical Trial.
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.
Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS; VRC 301 Study Team. Martin JE, et al. Among authors: enama me. Vaccine. 2008 Nov 25;26(50):6338-43. doi: 10.1016/j.vaccine.2008.09.026. Epub 2008 Sep 26. Vaccine. 2008. PMID: 18824060 Free PMC article. Clinical Trial.
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 009 Study Team; VRC 010 Study Team. Koup RA, et al. Among authors: enama me. PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015. PLoS One. 2010. PMID: 20126394 Free PMC article. Clinical Trial.
41 results